학술논문
CT-105 Post-Infusion Monitoring Costs and Health Care Resource Utilization (HCRU) by Site of Care (SOC) in Patients With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) Receiving Lisocabtagene Maraleucel (liso-cel) Treatment in the TRANSCEND CLL 004 (TRANSCEND) Study
Document Type
Abstract
Author
Source
In Clinical Lymphoma, Myeloma and Leukemia September 2023 23 Supplement 1:S516-S517
Subject
Language
ISSN
2152-2650